Ferroptosis Validation in Parkinson's Disease

Experiment Overview

Pathway Diagram

Code: PD-FERRO-001 Phase: Preclinical (in vitro) -> Clinical (Phase I/II) Status: Proposed Duration: 36 months

Rationale

Experiment Overview

Pathway Diagram

Code: PD-FERRO-001 Phase: Preclinical (in vitro) -> Clinical (Phase I/II) Status: Proposed Duration: 36 months

Rationale

This experiment validates the [Ferroptosis Hypothesis](/mechanisms/ferroptosis) by measuring [ferroptosis](/mechanisms/ferroptosis) markers in [Parkinson's disease](/diseases/parkinsons-disease) patient samples, testing [ferroptosis](/mechanisms/ferroptosis) inhibition in cellular models, and evaluating [iron chelation therapy](/therapeutics/iron-chelation-therapy-neurodegeneration) in early-stage [PD](/diseases/parkinsons-disease). [Ferroptosis](/mechanisms/ferroptosis) is an iron-dependent, [lipid peroxidation](/mechanisms/oxidative-stress)-driven form of cell death that has been implicated in [dopaminergic neuron](/cell-types/dopaminergic-neurons-substantia-nigra) loss in the [substantia nigra](/brain-regions/substantia-nigra) of [PD](/diseases/parkinsons-disease) patients[@ayton2022;@devos2020]. The [GPX4](/proteins/gpx4) antioxidant system is compromised in [PD](/diseases/parkinsons-disease), making [neurons](/cell-types/dopaminergic-neurons-substantia-nigra) vulnerable to [ferroptosis](/mechanisms/ferroptosis)-mediated death[@weiland2019].

Study Design

Phase 1: Biomarker Discovery (Months 1-12)

Objectives

• Identify ferroptosis biomarkers in PD patients vs. controls
• Characterize lipid peroxidation profiles
• Correlate biomarker levels with disease severity

Methods

• Cohort: 100 [Parkinson's disease](/diseases/parkinsons-disease) patients, 100 age-matched controls
• Samples: CSF, serum, [PBMCs](/cell-types/peripheral-blood-mononuclear-cells)
• Markers: 4-HNE, F2-isoprostanes, [GPX4](/proteins/gpx4) activity, ferritin, iron
• Assessment: [UPDRS](/diseases/parkinsons-disease), [MoCA](/diseases/parkinsons-disease), [MRI](/technologies/magnetic-resonance-imaging) R2* iron imaging

Endpoints

• Primary: CSF F2-isoprostanes difference PD vs. controls
• Secondary: Correlation with UPDRS, disease duration

Phase 2: Cellular Validation (Months 6-18)

Objectives

• Validate ferroptosis in PD patient-derived neurons
• Test ferroptosis inhibitors for neuroprotection

Methods

• Models: [iPSC](/technologies/ipsc-derived-neurons)-derived [dopaminergic neurons](/cell-types/dopaminergic-neurons-substantia-nigra) ([Parkinson's disease](/diseases/parkinsons-disease) patients, controls)
• Interventions: [Deferoxamine](/therapeutics/iron-chelation-therapy-neurodegeneration), ferrostatin-1, liproxstatin-1 ([ferroptosis](/mechanisms/ferroptosis) inhibitors)
• Outcomes: Cell viability, [lipid peroxidation](/mechanisms/oxidative-stress), iron levels

Endpoints

• Primary: Neuronal survival after intervention
• Secondary: Lipid peroxidation reduction

Phase 3: Clinical Trial (Months 18-36)

Objectives

• Evaluate deferasirox safety/tolerability in early PD
• Preliminary efficacy on disease progression

Design

• Type: Randomized, double-blind, placebo-controlled
• Arms: Deferasirox 20mg/kg, deferasirox 10mg/kg, placebo
• Duration: 12 months treatment, 6 months follow-up
• Cohort: 60 patients (20 per arm)

Endpoints

• Primary: Safety (adverse events), UPDRS change
• Secondary: CSF biomarkers, MRI iron imaging

Statistical Analysis

Power Calculation

• Phase 1: 80% power to detect 30% biomarker difference (α=0.05)
• Phase 3: 80% power to detect 3-point UPDRS difference

Analysis Plan

• Mixed-effects models for biomarker progression
• Kaplan-Meier for time to progression
• Correlational analysis biomarker-disease severity

Safety Considerations

• Iron chelation requires monitoring: hematologic, hepatic, renal
• MRI contraindications: metal implants
• Exclusion: Hemochromatosis, anemia, liver disease

Budget Estimate

| Phase | Cost (USD) |
|-------|------------|
| Phase 1 | $500,000 |
| Phase 2 | $800,000 |
| Phase 3 | $2,500,000 |
| Total | $3,800,000 |

Ethical Considerations

• IRB approval required
• Informed consent for all participants
• Data safety monitoring board

Risk Assessment

| Risk | Mitigation |
|------|------------|
| Iron chelation toxicity | Low-dose escalation, close monitoring |
| Insufficient biomarker signal | Multi-analyte approach |
| Patient enrollment | Multi-site recruitment |

Expected Outcomes

Related Mechanisms and Therapeutic Targets

This experiment connects [ferroptosis](/mechanisms/ferroptosis) to broader [neurodegenerative pathways](/mechanisms) relevant to [Parkinson's disease](/diseases/parkinsons-disease):

Key Mechanisms

• [Iron dysregulation](/mechanisms/metal-homeostasis-alzheimers): [Parkinson's disease](/diseases/parkinsons-disease) patients show elevated iron in the [substantia nigra](/brain-regions/substantia-nigra), creating a pro-ferroptotic environment
• [Oxidative stress](/mechanisms/oxidative-stress): [Lipid peroxidation](/mechanisms/oxidative-stress) is elevated in [PD](/diseases/parkinsons-disease); [4-HNE](/mechanisms/oxidative-stress) and [F2-isoprostanes](/mechanisms/oxidative-stress) are markers of this process
• [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction): [Dopaminergic neurons](/cell-types/dopaminergic-neurons-substantia-nigra) are particularly sensitive to [mitochondrial](/mechanisms/mitochondrial-dysfunction) dysfunction, which synergizes with [ferroptosis](/mechanisms/ferroptosis)
• [Neuroinflammation](/mechanisms/neuroinflammation): Microglial [iron](/mechanisms/metal-homeostasis-alzheimers) accumulation drives [neuroinflammation](/mechanisms/neuroinflammation), creating a feedforward loop with [ferroptosis](/mechanisms/ferroptosis)
• [Protein aggregation](/mechanisms/alpha-synuclein-pathology): [Alpha-synuclein](/proteins/alpha-synuclein) aggregates can disrupt [GPX4](/proteins/gpx4) function, linking [synucleinopathy](/diseases/parkinsons-disease) to [ferroptosis](/mechanisms/ferroptosis)

Therapeutic Targets

• Iron chelators: [Deferasirox](/therapeutics/iron-chelation-therapy-neurodegeneration), [deferoxamine](/therapeutics/iron-chelation-therapy-neurodegeneration) — reduce free iron, block [Fenton chemistry](/mechanisms/ferroptosis)
• Ferroptosis inhibitors: Ferrostatin-1, liproxstatin-1 — [lipid peroxidase](/mechanisms/ferroptosis) scavengers; [Deferoxamine](/therapeutics/iron-chelation-therapy-neurodegeneration) shown to be neuroprotective in [PD models](/diseases/parkinsons-disease)[@friedman2021]
• [GPX4](/proteins/gpx4) activators: Enhance endogenous antioxidant defense
• System Xc- inhibitors: Block cystine uptake, creating pro-ferroptotic conditions (therapeutic target to avoid)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Ferroptosis Validation in Parkinson's Disease discovered through SciDEX knowledge graph analysis: